More Manufacturing Woes for DPT as Batch Snafus Delay Imprimis Trial

DPT Laboratories continues to struggle with manufacturing issues, with one drugmaker complaining a pivotal trial has stalled due to DPT’s inability to produce placebos for the trial. Imprimis Pharmaceuticals said Monday that a Phase III clinical trial for its nonsteroidal anti-inflammatory drug Impracor (ketoprofen 10 percent cream) will be delayed because a placebo batch failed and an active batch showed a low specification result.
Drug Industry Daily